Bruno Bembi Selected Research

miglustat (Zavesca)

1/2020	Mechanistic convergence and shared therapeutic targets in Niemann-Pick disease.
3/2015	Enzyme replacement and substrate reduction therapy for Gaucher disease.
3/2015	Results from a 9-year Intensive Safety Surveillance Scheme (IS(3) ) in miglustat (Zavesca(®) )-treated patients.
2/2015	Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C.
9/2014	Effects of miglustat treatment in a patient affected by an atypical form of Tangier disease.
11/2013	Efficacy of miglustat in Niemann-Pick C disease: a single centre experience.
1/2010	Eye movement impairment recovery in a Gaucher patient treated with miglustat.
9/2009	Miglustat (Zavesca) in type 1 Gaucher disease: 5-year results of a post-authorisation safety surveillance programme.
3/2007	Pharmacological enhancement of mutated alpha-glucosidase activity in fibroblasts from patients with Pompe disease.
3/2007	Pharmacological Enhancement of Mutated α-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bruno Bembi Research Topics

Disease

24	Gaucher Disease (Gaucher's Disease) 12/2020 - 01/2005
17	Glycogen Storage Disease Type II (Pompe's Disease) 01/2020 - 09/2003
8	Disease Progression 06/2021 - 04/2010
6	Type C Niemann-Pick Disease (Niemann Pick Disease, Type C) 06/2021 - 11/2002
4	Splenomegaly 12/2021 - 08/2008
4	Muscular Diseases (Myopathy) 08/2014 - 03/2007
3	Neurologic Manifestations (Neurological Manifestations) 12/2020 - 02/2015
3	Parkinson Disease (Parkinson's Disease) 10/2017 - 07/2014
3	Pain (Aches) 01/2017 - 01/2013
3	Niemann-Pick Diseases (Niemann Pick Disease) 04/2016 - 08/2005
3	Mucopolysaccharidosis II (Hunter Syndrome) 04/2010 - 04/2006
2	Neurodegenerative Diseases (Neurodegenerative Disease) 11/2020 - 09/2009
2	Tangier Disease 01/2020 - 09/2014
2	Metabolic Diseases (Metabolic Disease) 12/2014 - 01/2014
2	Fabry Disease (Fabry's Disease) 07/2014 - 01/2004
1	Lung Diseases (Lung Disease) 12/2021
1	Epilepsy (Aura) 12/2020
1	Rare Diseases (Rare Disease) 01/2019
1	Muscular Atrophy (Muscle Atrophy) 01/2019
1	Cognitive Dysfunction 10/2017
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2017
1	Muscle Weakness 12/2015
1	Body Weight (Weight, Body) 03/2015
1	Ataxia (Dyssynergia) 09/2014
1	Lymphedema (Milroy Disease) 09/2014
1	Prurigo 09/2014
1	Dysarthria (Spastic Dysarthria) 09/2014
1	Deglutition Disorders (Dysphagia) 09/2014
1	Pancytopenia 09/2014
1	Late Onset Disorders 06/2014
1	Tay-Sachs Disease 05/2012
1	Globoid Cell Leukodystrophy (Krabbe Disease) 12/2010
1	Myalgia 04/2010
1	Lysosomal Storage Diseases (Lysosomal Storage Disease) 09/2009
1	Neuroblastoma 09/2009
1	Nephrotic Syndrome (Syndrome, Nephrotic) 08/2009
1	Myoclonic Epilepsies (Myoclonic Encephalopathy) 08/2009
1	Progressive Myoclonic Epilepsies (Progressive Myoclonic Epilepsy) 08/2009
1	Mucolipidoses (Sialidosis) 06/2009
1	Type B Niemann-Pick Disease 08/2008
1	Hepatomegaly 08/2008
1	Spontaneous Remission 04/2006
1	Inborn Genetic Diseases (Disease, Hereditary) 01/2006

Drug/Important Bio-Agent (IBA)

22	EnzymesIBA 12/2018 - 09/2003
15	AcidsIBA 12/2020 - 09/2003
11	Glucosylceramidase (Glucocerebrosidase)IBA 12/2018 - 01/2005
10	miglustat (Zavesca)FDA Link 01/2020 - 03/2007
8	GlucosidasesIBA 12/2020 - 03/2007
7	alpha-Glucosidases (Acid Maltase)IBA 01/2017 - 09/2003
6	Biomarkers (Surrogate Marker)IBA 06/2021 - 07/2014
5	GlycogenIBA 01/2017 - 03/2007
5	Glucosylceramides (Glucocerebrosides)IBA 01/2016 - 01/2005
4	LipidsIBA 11/2020 - 08/2008
4	imiglucerase FDA Link 03/2015 - 01/2010
3	GlycosphingolipidsIBA 01/2020 - 09/2009
3	DNA (Deoxyribonucleic Acid)IBA 08/2014 - 11/2002
3	Proteins (Proteins, Gene)FDA Link 07/2014 - 01/2004
3	CholesterolIBA 01/2014 - 09/2009
3	HydrolasesIBA 06/2009 - 03/2007
2	SphingomyelinsIBA 12/2021 - 01/2016
2	neodymium pyrocatechin disulfonate (NPD)IBA 01/2016 - 08/2005
2	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 01/2016 - 08/2005
2	Creatine Kinase (Creatine Phosphokinase)IBA 08/2014 - 04/2010
2	Complementary DNA (cDNA)IBA 04/2010 - 11/2002
2	Messenger RNA (mRNA)IBA 09/2009 - 04/2006
2	Imino SugarsIBA 03/2007 - 03/2007
2	SphingolipidsIBA 10/2005 - 01/2004
1	Ambroxol (Mucosolvan)IBA 12/2020
1	MicroRNAs (MicroRNA)IBA 01/2019
1	arimoclomolIBA 12/2018
1	7-ketocholesterolIBA 04/2016
1	eliglustatIBA 01/2016
1	Lysosomal Membrane ProteinsIBA 09/2015
1	ATP-Binding Cassette Transporters (ABC Transporters)IBA 09/2014
1	GadoliniumIBA 07/2014
1	alpha-SynucleinIBA 07/2014
1	chitotriosidaseIBA 01/2013
1	Hexosaminidase A (Hex A)IBA 05/2012
1	GalactosylceramidaseIBA 12/2010
1	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 04/2010
1	Mannose (D-Mannose)IBA 08/2009
1	beta-GlucosidaseIBA 08/2009
1	SandIBA 11/2007
1	Antihypertensive Agents (Antihypertensives)IBA 04/2006
1	RNA (Ribonucleic Acid)IBA 01/2006
1	NucleotidesIBA 01/2006
1	GlycolipidsIBA 01/2005
1	alpha-Galactosidase (Beano)IBA 01/2004
1	Glutamine (L-Glutamine)FDA Link 01/2004

Therapy/Procedure

14	Enzyme Replacement Therapy 01/2020 - 01/2005
12	Therapeutics 12/2020 - 03/2007
1	Splenectomy 10/2021
1	High-Protein Diet 01/2020
1	Ambulatory Care (Outpatient Care) 01/2019
1	Drug Prescriptions 01/2019
1	Denervation 01/2017
1	Enzyme Therapy 01/2017
1	Breathing Exercises 12/2015